Cancer related traits |
---|
Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) |
Adverse response to chemotherapy in breast cancer (alopecia) |
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) |
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) |
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) |
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) |
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) |
Anthracycline-induced cardiotoxicity in childhood cancer |
Bladder cancer |
Bladder cancer (smoking interaction) |
Body mass index (change over time) in cancer |
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease |
Body mass index (change over time) in gastrointestinal cancer |
Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease |
Body mass index (change over time) in lung cancer |
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease |
Breast cancer |
Breast cancer (early onset) |
Breast cancer (estrogen-receptor negative |
Breast cancer (estrogen-receptor negative) |
Breast cancer (estrogen-receptor positive) |
Breast cancer (male) |
Breast cancer (menopausal hormone therapy interaction) |
Breast cancer (prognosis) |
Breast cancer (survival) |
Breast Cancer in BRCA1 mutation carriers |
Breast cancer in BRCA2 mutation carriers |
Breast cancer-free interval (treatment with aromatase inhibitor) |
Cancer |
Cancer (pleiotropy) |
Cardia gastric cancer |
Cervical cancer |
Colon cancer |
Colorectal cancer |
Colorectal cancer (alcohol consumption interaction) |
Colorectal cancer (aspirin and/or NSAID use interaction) |
Colorectal cancer (calcium intake interaction) |
Colorectal cancer (diet interaction) |
Colorectal cancer (interaction) |
Colorectal cancer (oestrogen-progestogen hormone therapy interaction) |
Colorectal or endometrial cancer |
Disease-free survival in breast cancer |
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer |
Endometrial cancer |
Epithelial ovarian cancer |
Erectile dysfunction and prostate cancer treatment |
Esophageal cancer |
Esophageal cancer (alcohol interaction) |
Esophageal cancer (squamous cell) |
Esophageal cancer and gastric cancer |
Esophageal squamous cell cancer (length of survival) |
Estradiol plasma levels (breast cancer) |
Estrogen receptor status in breast cancer |
Estrogen receptor status in HER2 negative breast cancer |
Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer |
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer |
Gallbladder cancer |
Gastric cancer |
Lobular breast cancer (menopausal hormone therapy interaction) |
Lung adenocarcinoma |
Lung cancer |
Lung cancer (asbestos exposure interaction) |
Lung cancer (DNA repair capacity) |
Lung cancer (smoking interaction) |
Multiple cancers (lung cancer |
Multiple keratinocyte cancers |
Non-cardia gastric cancer |